Holmium laser enucleation of the prostate in Jehovah’s Witness patients
To evaluate if HoLEP is a viable option for male patients with medication-refractory urinary symptoms due to an enlarged prostate who are surgical candidates, but do not accept blood product transfusion.
Materials and methods
Between August 2008 and March 2019, nine Jehovah’s Witness patients were undergoing HoLEP for relief of lower urinary tract symptoms and urinary retention. We described change in hemoglobin, change in PSA, enucleated prostate weight, enucleation and morcellation times, length of stay, and postoperative retention rate.
The average age was 71.4 years (range 53–87). Urinary retention requiring catheterization was present in seven patients (78%). Two patients had a known diagnosis of prostate cancer preoperatively. The mean preoperative PSA on average was 21.6 ng/dL. Patients had a wide range of gland sizes, with a mean enucleated weight of 141 g (range 18–344 g). Mean reduction in hemoglobin was 16.9% following HoLEP. All patients managed to void postoperatively. All but one patient went home on postoperative day 1, and this patient went home on postoperative day 2. No patients required blood product transfusion or return to the operating room for clot irrigation postoperatively.
HoLEP is a reasonable option for Jehovah’s Witness and other patients with contraindications to blood product transfusion requiring surgical management of urinary symptoms due to enlarged prostate.
KeywordsHolmium laser enucleation of the prostate Benign prostate hyperplasia Jehovah’s Witness Lower urinary tract symptoms
Benign prostate hyperplasia
Holmium laser enucleation of the prostate
Lower urinary tract symptoms
Transurethral resection of the prostate
AS: protocol/project development, data collection or management, data analysis, and manuscript writing/editing. CUN: data collection or management, data analysis, and manuscript writing/editing. NEY: data collection or management, and data analysis. CAD: data collection or management, and data analysis. MSB: data collection or management, and data analysis. RSB: protocol/project development, data collection or management, and data analysis. JEL: protocol/project development, data collection or management, data analysis, and manuscript writing/editing.
Compliance with ethical standards
Conflict of interest
The following disclosures are listed as follows. JE Lingeman is a consultant for Boston Scientific and Lumenis. CA Dauw is a consultant for Boston Scientific. MS Borofsky is a consultant for Boston Scientific and Auris Health. All other authors declare no conflict of interest.
Research involving human participants and/or animals
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Institutional review board approval was approved at our institution (number 101000224).
Informed consent was not obtained on patients given the retrospective nature of the study. The study was approved by the IRB at our institution (number 101000224).
- 3.How Many of Jehovah’s Witnesses Are There Worldwide? JW.ORG. https://www.jw.org/en/jehovahs-witnesses/faq/how-many-jw-members/. Accessed 14 Feb 2019
- 4.Why Don’t Jehovah’s Witnesses Accept Blood Transfusions? JW.ORG. https://www.jw.org/en/jehovahs-witnesses/faq/jehovahs-witnesses-why-no-blood-transfusions/. Accessed 14 Feb 2019
- 7.Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC (1989) Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 167(2 Pt 2):999–1003 (discussion 1004) Google Scholar
- 8.Gilling PJ, Kennett K, Das AK, Thompson D, Fraundorfer MR (1998) Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation: an update on the early clinical experience. J Endourol 12(5):457–459. https://doi.org/10.1089/end.1998.12.457 CrossRefPubMedGoogle Scholar
- 9.Gilling PJ, Wilson LC, King CJ, Westenberg AM, Frampton CM, Fraundorfer MR (2012) Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int 109(3):408–411. https://doi.org/10.1111/j.1464-410X.2011.10359.x CrossRefPubMedGoogle Scholar
- 11.Yin L, Teng J, Huang C-J, Zhang X, Xu D (2013) Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. J Endourol 27(5):604–611. https://doi.org/10.1089/end.2012.0505 CrossRefPubMedGoogle Scholar
- 12.Wilson LC, Gilling PJ, Williams A et al (2006) A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. Eur Urol 50(3):569–573. https://doi.org/10.1016/j.eururo.2006.04.002 CrossRefPubMedGoogle Scholar
- 18.Mitchell CR, Mynderse LA, Lightner DJ, Husmann DA, Krambeck AE (2014) Efficacy of holmium laser enucleation of the prostate in patients with non-neurogenic impaired bladder contractility: results of a prospective trial. Urology 83(2):428–432. https://doi.org/10.1016/j.urology.2013.09.035 CrossRefPubMedGoogle Scholar
- 24.Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC (2002) Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J Urol 168(5):2024–2026. https://doi.org/10.1097/01.ju.0000028607.29093.56 CrossRefPubMedGoogle Scholar
- 25.Yang T-Y, Chen M, Lin W-R et al (2018) Preoperative treatment with 5α-reductase inhibitors and the risk of hemorrhagic events in patients undergoing transurethral resection of the prostate—a population-based cohort study. Clin Sao Paulo Braz 73:e264. https://doi.org/10.6061/clinics/2018/e264 CrossRefGoogle Scholar
- 34.Kuntz RM, Lehrich K (2002) Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm.: a randomized prospective trial of 120 patients. J Urol 168(4 Pt 1):1465–1469. https://doi.org/10.1097/01.ju.0000027901.47718.fc CrossRefPubMedGoogle Scholar